Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21468656 | 0.81 | KDM1A (0.38) | CYP19A1KDM1ASIGMAR1KMT2AJMJD6 | |
| SCHEMBL18222497 | 0.79 | CYP19A1 (0.44) | CYP19A1KDM1ASIGMAR1KMT2AJMJD6 | |
| SCHEMBL18222561 | 0.79 | CYP19A1 (0.40) | CYP19A1KDM1ASIGMAR1KMT2AJMJD6 | |
| SCHEMBL2629335 | 0.76 | — | — | |
| SCHEMBL21438556 | 0.75 | HTT (0.31) | SIGMAR1 | |
| SCHEMBL7810321 | 0.75 | — | — | |
| SCHEMBL17662636 | 0.72 | NUDT1 (0.43) | CYP19A1KDM1AKMT2AJMJD6KEAP1 | |
| SCHEMBL17662643 | 0.72 | JMJD6 (0.43) | CYP19A1KDM1ASIGMAR1KMT2AJMJD6 | |
| SCHEMBL20260762 | 0.71 | KDM1A (0.43) | CYP19A1KDM1ASIGMAR1JMJD6 | |
| SCHEMBL21438793 | 0.70 | BUB1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4352060-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022261159-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20210139514-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139514-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CYP19A1 4865/4885KDM1A 4635/4885SIGMAR1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.